Noble Financial Predicts MAIA Biotechnology FY2026 Earnings

MAIA Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) - Equities research analysts at Noble Financial issued their FY2026 earnings estimates for shares of MAIA Biotechnology in a report issued on Wednesday, November 18th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of ($0.54) for the year. The consensus estimate for MAIA Biotechnology's current full-year earnings is ($0.48) per share. Noble Financial also issued estimates for MAIA Biotechnology's Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.54) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01.

MAIA Biotechnology Stock Down 12.3%

MAIA Biotechnology stock opened at $1.14 on Friday. The business's 50-day simple moving average is $1.17 and its 200 day simple moving average is $1.38. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19. The stock has a market cap of $70.39 million, a price-to-earnings ratio of -2.43 and a beta of 0.28.

Insider Buying and Selling

In other MAIA Biotechnology news, CEO Vlad Vitoc acquired 73,000 shares of the business's stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of $1.37 per share, with a total value of $100,010.00. Following the completion of the transaction, the chief executive officer directly owned 1,049,121 shares in the company, valued at $1,437,295.77. This trade represents a 7.48% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ramiro Guerrero purchased 37,595 shares of MAIA Biotechnology stock in a transaction that occurred on Thursday, September 10th. The shares were bought at an average cost of $1.32 per share, with a total value of $49,625.40. Following the completion of the transaction, the director directly owned 773,296 shares of the company's stock, valued at approximately $1,020,750.72. The trade was a 5.11% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 246,179 shares of company stock worth $336,125 over the last quarter. 19.81% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Centric Wealth Management acquired a new stake in shares of MAIA Biotechnology in the second quarter valued at approximately $1,107,000. Cable Car Capital LP acquired a new stake in MAIA Biotechnology during the 2nd quarter valued at $741,000. BlackRock Inc. bought a new position in shares of MAIA Biotechnology in the second quarter valued at about $580,000. Corsair Capital Management L.P. bought a new position in shares of MAIA Biotechnology in the first quarter valued at about $140,000. Finally, Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology during the 3rd quarter worth about $100,000. Institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Company Profile

(Get Free Report)

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company's lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.

Further Reading

Earnings History and Estimates for MAIA Biotechnology (NYSEAMERICAN:MAIA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MAIA Biotechnology Right Now?

Before you consider MAIA Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.

While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines